Needham Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)

July 28, 2026 7:16 AM

Needham analyst Joseph Stringer reiterated a Buy rating and $83.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).The analyst commented: "APLD ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found